In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Monte Rosa Therapeutics (GLUE – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $7.51.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Cue Biopharma, and Moderna. According to TipRanks, Tenthoff has an average return of 1.2% and a 37.15% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Monte Rosa Therapeutics with a $14.25 average price target.
GLUE market cap is currently $376.7M and has a P/E ratio of -2.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monte Rosa Therapeutics (GLUE) Company Description:
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates.
Read More on GLUE:
- 5 Stocks that Analysts Love in March 2024
- Monte Rosa Therapeutics Unveils Corporate Strategy Presentation
- Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Monte Rosa Therapeutics announces anticipated upcoming milestones
- Monte Rosa Therapeutics expects cash to fund operations into 1H26
